

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: A61K 45/06 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and
(72) Inventors: SIEMEISTER, Gerhard [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). HABEREY, Martin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). THIERAUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use (II)

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1 5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during 10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce 15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also 20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and 25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonneuve et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was 30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonneuve et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led 5 to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., *J. Clin. Invest.* 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., *Cancer Res.* 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., *Br. J. Cancer* 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996), as well as elevated expression of Flt4 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., *Cancer Res.* 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., *Am. J. Pathol.* 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., *Science* 284, 1994-1998, 1999; Holash et al., *Oncogene* 18, 5356-5362, 1999).

30 Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., *J. Clin. Invest.* 103, 159-165, 1999; Lin et al. *Proc. Natl. Acad. Sci. USA* 95, 8829-8834, 1998; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 15 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon 25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby 30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological 10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems.

Targeting or modulation of the biological activities of VEGF/VEGF receptor 15 systems and of Angiopietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,

(b) compounds which inhibit ligand binding to receptors,

20 (c) compounds which inhibit activation of intracellular signal pathways of the receptors,

(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

25 (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

(f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al.,

Proc. Am. Assoc. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca:

5 ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Assoc. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is

10 prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin

15 A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer Res. 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas

20 (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 25 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.


30

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

15



20

I,

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II;




5

wherein the binding is via the two terminal C- atoms, and
m has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or

20 $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T independently from each other have the meaning of N or CH,

25 with the proviso that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
X has the meaning of imino, oxa or thia;
5 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
10 more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example
anthranyl acid derivatives of general formula IV

30

11




in which

A has the meaning of group $=NR^2$,

5 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z has the meaning of the group $=NR^{10}$ or $=N-, -N(R^{10})-$ $(CH_2)_q-$, branched or unbranched C₁₋₆-Alkyl or is the group


10



15

or A, Z and R¹ together form the group

20



m, n and o

has the meaning of 0 – 3,

q

has the meaning of 1 – 6,

 $R_a, R_b, R_c, R_d, R_e, R_f$ independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,

5

10

 X has the meaning of group $=NR^9$ or $=N-$, Y has the meaning of group $-(CH_2)_p$, p

has the meaning of integer 1-4,

 R^1 has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

15

 R^2 has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,


20

 R^3 has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,

25

 R^4, R^5, R^6 and R^7 independently from each other have the meaning of hydrogen, halogen or C_{1-6} -alkoxy, C_{1-6} -alkyl or


C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R^5 and R^6 together form the group



5 R^8 , R^9 and R^{10} independently from each other have the meaning of hydrogen or C_{1-6} -alkyl,
as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




15 V,



in which

R^1 has the meaning of group





20




14



in which R^5 is chloro, bromo or the group $-\text{OCH}_3$,



in which R^7 is $-\text{CH}_3$ or chloro,




in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$

in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

5

R^2 has the meaning of pyridyl or the group



10

and

R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under 15 compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of 25 main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least 10 one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59. Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims 30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.
Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred
10 pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical
15 compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2, and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

20 The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

25 The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites

5 formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, 10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as

15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients 25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch.

The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to interference with one
ligand/receptor system overlaps with the biological response to interference with a
second ligand/receptor system. Alternatively, combined functional interference
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via
Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to functional interference with a
ligand/receptor system overlaps in time with targeting of cytotoxic agents.

15 The invention is also directed to a substance which functional interferes with both
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor
systems.

20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,
VEGF-D, PIGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal
purposes. Such diseases are, for example, cancer, cancer metastasis,
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
30 the present invention can be applied orally, parenterally, or via gene therapeutic
methods.

Therefor the present invention also concerns the use of pharmaceutical
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector 15 (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppi et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of 5 the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of 10 intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of 5 approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex 10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly 15 shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is
5 superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate
10 (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods
15 described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor
20 growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

		mode of treatment
treatment group	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
10 coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the
20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a 5 volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by 10 means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single 15 intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

	mode of treatment	
treatment group	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a 10 reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducting L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate 15 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the

5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

mock, con.	=	treatment group 1
mock+VEGF-A	=	treatment group 2
10 sTIE2-cl13	=	treatment group 3
sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of

15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-

30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in 5 Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine 10 kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
5
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
10
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
20
- 25 4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 30 5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

10

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.

10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of

- 20 a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 25 e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 30 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

25 14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.


30 15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of genaral formula I



in which


5 r has the meaning of 0 to 2,
 n has the meaning of 0 to 2;

R₃ und R₄ a) each independently from each other have the
 meaning of lower alkyl,
 10 b) together form a bridge of general partial formula
 II,



15 wherein the binding is via the two terminal C- atoms,
 and
 m has the meaning of 0 to 4; or
 c) together form a bridge of partial formula III

20




has	wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the binning is via the atoms T_1 and T_4 ;
5	
G	has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ – alkylene or $C_2 - C_6$ – alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa (-O-), thia (-S-) or imino (-NH-),
10	
A, B, D, E and T	independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,
15	
Q	has the meaning of lower alkyl, lower alkyloxy or halogene,
R_1 and R_2	independently from each other have the meaning of H or lower alkyl,
X	has the meaning of imino, oxa or thia;
20	
Y	has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
Z	has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single
25	
30	

or double bonds; or an N-oxide of said compound,
wherein one or more N-atoms carry an oxygen atom,
or a salt thereof,

and/or a compound of general formula IV

5




in which

A has the meaning of group =NR²,

10 W has the meaning of oxygen, sulfur, two hydrogen atoms
or the group =NR⁸,


Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-
(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the
group

15



or A, Z and R¹ together form the group

20




5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	$R_a, R_b, R_c, R_d, R_e, R_f$	independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/ or R_a and/ or R_b together with R_c and or R_d or R_e together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,
10	X	has the meaning of group $=NR^9$ or $=N-$,
	Y	has the meaning of group $-(CH_2)_p$,
	p	has the meaning of integer 1-4,
15	R^1	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R^2	has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,
	R^3	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally
25		

45

substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,


5 R⁴, R⁵, R⁶ and R⁷ independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R⁵ and R⁶ together form the group



10 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts,

and/ or a compound of general formula V

15




V,

20

in which


R¹ has the meaning of group

46




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,




in which R^8 is -CH₃, fluoro,
chloro or -CF₃

in which R^4 is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R^6 is
-CH₃ or chloro

5

R^2 has the meaning of pyridyl or the group



10

and

R^3 has the meaning of hydrogen or fluoro, as well as their
isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as
15 compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium
20 hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, Tie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium


hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.



19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the
production of a medicament for the treatment of tumors, cancers, psoriasis,
arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye
diseases, such as diabetic retinopathy, neovascular glaucoma, kidney
diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation
rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver,
mesangial cell proliferative diseases, arteriosclerosis, damage of nerve
tissues, suppression of the ascites formation in patients and suppression of
VEGF oedemas.

**Fig. 1**

**Fig. 2****Fig. 3**






Fig. 4

**Fig. 5****Fig. 6**

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15 <140>

<141>

<160> 59

20 <210> 1

<211> 1835

<212> DNA

<213> Human

25 <400> 1

ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttg 60
agctctttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaat ttttttaat agtcacattc agctcgcttgc 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttata cgttaaccgta 240
tatacaaaca gccaaaaaac cataatggtg ccacaggat ggagcaggga 300
taacgtgtcc tctagtctat cttcgctaaa cagaaccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagtta 420
aagcaaaaga gacatcctt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
30 tggagttaat gggaccagga ttggaggact cttagctgat acagattca gtacgatttc 600
attaaaaaggc ttggatgtta agagaggaca ctcagcggtt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatcttac aaccaaatttgc 720
catttaagcg acaacaaaaaa aaggcaaacc cccaaacgca acctaaccac agcaaaatct 780
35 aagcaaaatc agacaacgaa gcagcgatgc atagcttcc tttgagagaa cgcataacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagctt acagtaggat tattgtata 900
aaaatgactc aagcgatgca aaaagttca tctgttccca gaatccgagg gagaactgag 960
gtgatcggtt gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
40 gccgagtctt cggaaggaca tctggacacc actttcagcc acctccttgc agggggcaca 1080
tccgccaaag tcatccttta ttccgagtaa taacttaat tccttctaa catttacacg 1140
45 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac ggtacgcgc ttccatgaga aaggatattt ggcaattttt tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatq ttaaaacgcca tcaggggctt ctcctccgt 1320
50 ttctgcccagg ggctttctt gtcttctctt tgccgagctc gtgggcagat cttctctgg 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcgc tctggtcgtc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccttc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtcccac attcgctacc actctgttcc acgtcatcca 1560
55 ggtacacgag ctgcgtgttag gccgtgctgt ctggggctcg aggctcttcc tgctggtgct 1620
cttggacggg cgggttagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagcttttg gagaatcaat gtatgaatgt ctaacctgac cggtggaccc gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaaagc ggct

60 <210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gtttattca gtaattagct cttaagaccc ctggggcctg tgctaccag 60
 acactaacaa cagtcttat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtggtgaccc cgggagctat ttgcctgtt 180
 agtgcacaca cctggaaaca tactgcttc atttttcat ccacatcagt gagaaatgag 240
 tggcccgta gcaagatata actatgcaat catgcaacaa agctgcctaa taacattca 300
 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 10 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcc tggtttctct 420
 aaatgtcaag ctttgactga aaactcccgt tttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaattt gatgggagag aaggaaataa gtacttgaaa tgtaggccct 540
 caccctccca tgacatcctc catgagcctc ctgatgttagt g

15 <210> 3

<211> 516
 <212> DNA
 <213> Human

20 <400> 3

tagagatgtt ggttcatgac ccccggtatc tggagcagat gaatgaagag tctctggaa 60
 tcagcccaaga catgtgcac tacatcacag aggacatgtt catgtcgccg aacctgaatg 120
 25 gacactctgg gttgattgtt aaagaaattt ggttccac ctcgagctt tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactataatgtt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcac tgcaggctt tgcaggaca ctgctcagat ttacacccctt ggtgtggcc 360
 atgaactgga tgaggaaggc ctctatttgc acagttgtt ggcccgacat tgcaccaaca 420
 30 tccaagatgc tttccagtc aaaagaacca gcaaataactt ttctctggat ctcactcatg 480
 atgaagttcc agagttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

40 cccacaacac agggccctg aaacacgcca gcctctccctc tgggtcagc ttggccca 60
 cctgctcact ggatcacacg ccattgttagg tggggcatgg tggggatcag ggcccttggc 120
 ccacggggag gtagaagaag acctggtcg tggtaagggtc tgagaagggtg ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgcctca tccccccggc gaggcagcga cacagcagg 240
 gcaccaactc cagcaggta agcaccagg agatgagttc aaccaccaac atgaagatga 300
 tgaagatgtt ctctccgtt gggcgagaga caaaggatgtt cagcaggtag gggcagggtg 360
 45 ctcgctggca cacaacacg ggctccatgg tccagccgtt caggcgccac tggccataga 420
 ggaaggctgc ctctagcaca ctcttgccatgg gcacacttgc gacatagggtg cccatcagt 480
 ctccgcggat ggcaggcgtt ccatcttgc ccaccggat ctggccatc tgacgctcta 540
 cggccgcac cggccgcctt acctgtgggt cttggccgg cagtgcgcgc agctccccc 600
 50 ccttctgccc cagccgcctt tctcgccgtt acaggtaat gacatggccc aggttagacca 660
 gggtggtgtt gctgacgaaag agaaacttgc acacccagta gggatgtt gggatgggaa 720
 aggctggtc atagcagacg ttgggtgcagc ctgggtggc cgtgttacac tcgaaatctg 780
 actgctcgcc accccacact gactcgccgg ccaggcccag gatgaggatg cggaaatg 840
 agagcaccgt cagccagatc ttacccacca cggtcagatg ctccctggacc tggccagca 900
 55 acttctccac gaagccccag tcacccatgg ctccccggcc tccgtcgccca aggagacaga 960
 gcacgtcagt gtgtcagcat ggcacatcctc tggatcgccca agcaacaacg ctgcaggag 1020
 gtctgccacg cccgttctac cgcctgcctg cggggcgcc caggtggagg tggggacat 1080
 ggcggagtg acgccccgcg

60 <210> 5
 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctgggtt caggatgttg ggagacacag cgagactctg tctccaaaaa 60

aaaaagtgct tttgaaaaat gttgagggtt gaaatgatggg aaccaacatt ctttggattt 120
 agtggggagc ataatagcaa acacccctt gggtcgacata tgtacaggaa tgggaccag 180
 ttggggcaca gccatggact tccccccctt ggaatgtgt gtcgaaagtg gggccaggc 240
 5 ccagacccaa gaggagaggg tggtccgcag acaccccggtt atgtcagcat ccccccacct 300
 gccttctggc ggcacccccc ggggtctgtt tttagtcaac aggcattccctt cttcagccctt gacttggcc 420
 gtatatgctg ggaacagggtt gcaaggggcca agcgttccctt cttcagccctt gacttggcc 480
 atgcacccccc tctcccccac acacaaacaa gcacttctcc agtatgggtc caggacaggt 540
 gtccttcag tcctctgggtt atgacctcaa gtcctacttg ggcctgcag cccagcctgt 600
 10 gttgtaacct ctgcgtccctt aagaccacac ctggaagatt ctcttcctt ttgaaggaga 660
 atcatcattt gtgcttatac acttctaaga cattttgtac ggcacggaca agttaaacag 720
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 780
 ctgggcaggc ttctctgttag aaccccgagg gcttcggccc agaccacagc gtcttgcctt 840
 gagcctagag cagggagttcc cgaacttctg cattcacaga ccaccccttcc aattgttata 900
 15 accaaaggcc tcctgttctg ttatttcaact taaatcaaca tgctattttt ttttcaactca 960
 ctctgactt tagcctcgtt ctgagccgtt tatccatgca gtcatgttca cgtgcttagtt acgttttctt tcttacacat gaaaataaaat gcataagtgt tagaagaaaa aaaaaa

<210> 6
 <211> 2313

20 <212> DNA
 <213> Human

<400> 6

25 ccagagcagg cctgggtggg agcagggacg gtgcaccgga cggcgggatc gagcaaatgg 60
 gtctggccat ggagcacgga gggtcctacg ctcggggggg gggcagctct cggggctgct 120
 ggtattacct gcgctacttc ttccctttcg tctccctcat ccaattccctt atcatcctgg 180
 ggctcgtgct cttcatggtc tatggcaacg tgacgtgag cacagagtcc aacctgcagg 240
 ccaccgagcg ccgagccgag ggctataca gtcagctctt agggctcacg gcctcccaat 300
 30 ccaacttgcac caaggagctc aacttcacca cccgcgcacca ggatgccatc atgcagatgt 360
 ggctgaatgc tcgcccgcac ctggaccgca tcaatgccag ctccgcctt tgccagggtt 420
 accgggtcat ctacacgaac aatcagaggt acatggcttc catcatctt agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgctga 540
 atcagaagggtt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcaactaagg 600
 35 ataaggaaag cgtgctgctg aacaaacgcg tggcggagga acagctgggtt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcgcg actggccaaag gagcaactgc aaaaggtgca 720
 agccctctgc ctgcccctgg acaaggacaa gttgagatg gaccttcgtt acctgtggag 780
 ggactccatt atccccacgca gcctggacaa cctgggttac aacctctacc atccccctggg 840
 40 ctcggaattt gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag ctggcccgaa gcctccggcgg gatatcgaa cgctggccc gcgagaactc 960
 agacctccaa cgccagaagc tggaaagccca gcagggccctg cgggcccgtc aggaggcgaa 1020
 acagaagggtt gagaaggagg ctcaggcccg ggaggccaaag ctccaagctg aatgctcccg 1080
 gcagacccag cttagcgttgg aggagaaggc ggtgctgccc aaggaacgag acaacctggc 1140
 caaggagctg gaagagaaga agagggaggc ggagcagctc agatggagc tggccatcag 1200
 45 aaactcagcc ctggacaccc gcatcaagac caagtcgcac ccgatgatgc cagtgtcaag 1260
 gcccattggc cctgtccca acccccaccc catcgacccca gctagcctgg aggagttcaa 1320
 gaggaagatc ctggagtccc agaggcccccc tgcaggcatc cctgttagccc catccagtg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggcccgatc ctcggcggtt tgccggaggat 1440
 gcagggatat gctcacagcg cccgacacaaa cccctcccg ccggcccccac ccacccagg 1500
 50 ccaccatcag acaactccct gcatgcaaaac cccttagtacc ctctcacacc cgcacccgcg 1560
 cctcacgatc cctcacccag agcacacgcg cgcggagatg acgtcacgcg agcaacggcg 1620
 ctgacgtcac atatcaccgt ggtatggcg tcacgtggcc atgttagacgt cacgaagaga 1680
 tatagcgatg gcgtcgttca gatgcagcac gtcgcacaca gacatggggaa acttggcatg 1740
 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800
 55 tcacacagac gcccgcgttcc catcacacag acgggtatgatc tgcacacac agacacagt 1860
 acaacacaca ccatgacaaac gacacccata gatatggcac caacatcaca tgcacgcac 1920
 ccccttcaca cacacttttcc accaaatttcc cacctagttt cacgttcccc cggccctggc 1980
 acacgggcca aggtacccac aggtacccat cccctcccg acagccctgg gcccagcac 2040
 60 ctcccttcctt ccagcttcctt ggcctcccg ccacttcctt acccccagtg cctggacccg 2100
 gaggtgagaa caggaagccca ttcacctccg ctcccttgatc gtgagttttt ccaggaccc 2160
 ctggggccccc tgagccgggg gtgagggtca cctgttgcgtt ggaggggagc cactccttct 2220
 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaaaaa aaaaaaaaaaaa aaa

65 <210> 7
 <211> 389

<212> DNA
 <213> Human

<400> 7

5 gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
 gccactggat tcatgtctag aaaagatagg ataattctg taaagaatg aagaccttgc 120
 tattctaaaa tcagatcctt acagatccag attcagggaa acaaatacat aggggactaa 180
 10 ctttccttgt tcagattagt ttttccttgc acacccagc tatataatg gaggaagtat 240
 tgactttta aaagtgtttt agtttccat ttctttgata tgaaaagtaa tatttcggga 300
 gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggct gaatttggc 360
 tcctttgtg gtgtccagtg ggttaacatc

<210> 8

15 <211> 157
 <212> DNA
 <213> Human

<400> 8

20 tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtat 60
 gaagcagggaa gcaagccac tcaaacgtga aatttggcat gaggatcca gtaactttct 120
 cctcaatctg tgaactataat gtgagtttga tattttg

<210> 9

25 <211> 561
 <212> DNA
 <213> Human

30 <400> 9

aatagtcaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagt 60
 gatgttgtt gctgacatac agctcagcc agcagagaaa gaattctgaa ttccccttgc 120
 35 tgaactgaac tattctgtt catatggttt acaaattctgt gtgttatttc ttttctacct 180
 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
 tcctgatttt ttgcctgatt aatctctgtt gagctctact tgggtcatt caagattta 300
 tcatgttggaa agaaaaagtg aatatgaccc taaaaatttgc tattttgggt gatgatagtc 360
 tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgatataa 420
 40 ttaaacctat aatgagttt ctaatggag aattcttaat ggatggatta tcccctgatc 480
 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
 ctgccccat ttcttaggaaa a

<210> 10

45 <211> 1508
 <212> DNA
 <213> Human

<400> 10

50 cacaacacg agagactcca cggctcgctt gggccacccgc agcctccatg gctccagcac 60
 tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
 gggtcgcgga gcagtcacgg gacaagtacc agcagcagct cctctgaaca gagactgcta 180
 ggatcatcct tctcctccgg gcctgttgc tgcataa tccgggtgca acccaaact 240
 55 gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
 aggtgtgagg actgtggccaa gtgcataatgt aaggagtgc cctacccaaag gcctctgcca 360
 tcagacttggaa tctgcgacaa gcagtcctt tgctcgcccc agaacgtgat tgactatggg 420
 acttgtgtat gctgtgtgaa agtctcttc tatcactgtt ctaatgtga tgaggacaac 480
 tggctgaca acccatgttc ttgcagccag tctcactgtt gtacacgtat gtcagccatg 540
 ggtgtcatgt ccctctttt gccttgttta tggtgttacc ttccagccaa gggttgcctt 600
 60 aaatttgtgcc aggggtgtt tgaccgggtt aacaggcctg gttggccctg taaaaactca 660
 aacacagttt gctgcaaagt tccactgtc ccccccggatg actttgaaaa accaacatag 720
 catcattaat caggaatatt acagtaatga ggatttttc tttctttttt taatacacat 780
 atgcaaccaa ctaaacagtt ataatcttgg cactgttaat agaaagtgg gatagtctt 840
 gctgtttgcg gtgaaatgt tttgtccat gtgcgtttt aactgatatg cttgttagaa 900
 65 ctcagctaattt gtagctcaaa gtagtggatc cagaacttgg tgacccatgtt attgcataag 960
 ctaaagcaac acagacactc ctaggcaaaag ttttgggggg tgaatagttac ttgcaaaact 1020

tgtaaattag cagatgactt tttccattt ttttctccag agagaatgtg ctatatttt 1080
 gtatatacaa taatatttc aactgtgaaa aacaagtggt gccatactac atggcacaga 1140
 cacaatataat tatactaata tttgtacat tcggagaat gtgaatcaat cagtatgtt 1200
 5 ttagattgtt tttgcctt cagaaagcct ttattgtaa actctgattt ccctttggac 1260
 ttcatgtata ttgtacagt acagtaaaat tcaacctta tttctaatt tttcaacat 1320
 atgttttagt gtaaagaata tttatttcaa gttttattat ttataaaaaa agaatattt 1380
 ttttaagagg catcttacaa atttgcccc tttatgagg atgtgatagt tgctgcaa 1440
 gaggggttac agatgcatat gtccaaataa aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaaaa
 10 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11

 gggcaggtga tcagggcaca catttccgt ccattgagac agtagcattc ccggcaccca 60
 20 tcgtgccagc tctcctcatt tttatgtga tgaccatcca cggtagaca agtgcggac 120
 aggtgggtg gcccagctga agcacaggcc gctctgact tgcagataag acagccgtga 180
 ctgtcctgct gaaaacccaa gggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgcacagcc gtgcttattt ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt ctgggcctt gggggcact cacagatctc acagtttgg 360
 25 acctcgcccg cgaccacgct ggttaccga

 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12

 tttttttttt ttggattgca aaaatttatt aaaattggag acactgttt aatcttctt 60
 35 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggctgagg atcacttgag 120
 cccagaagg ttgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgt tgcttgggt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa tacaaatgtg tgatgctgt tagtagagta 300
 acctcagaat caaaatggaa cggtttaca gtgatatcat tatatttcat ttggcagaat 360
 40 cattacatca ttggttacac tggaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcctt 480
 ctcaatttcc ttctcagtc cattttact tttaaacagc taatcactcc catctacaga 540
 ttaaggtgta tatgccacca aaaccttttgc cccattttaa aatttccctt aaagtttaaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 45 cacacagtgt agtcaagccg actctccata cccaaagcaag tcatccatgg ataaaaacgt 720
 taccaggagc agaaccatta agtggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tggccatg gttgagttt ggcttgctct ttaggactt 840
 agtagctatt ctcatccttc ctggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcattt gcacccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960
 50 ataagagttc tttgatgac g

 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13

 ataactacag ctccagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 60 aagagagccc ggccgcagag catgtgactg ctgggaccc tggataggc aacactgccc 120
 tctctcccccc agagcgaccc cccggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacacttc ttactgcca cctgcaatca tgctgtgaag atgactgggt 240
 gtggcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattt ctgaggacta ctgaaccttgc tttgctttt ttaaaaaata ctaaatcctc 360
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t

 <210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagttgtgg agaacaggtt gagtagagca acaacaacaa aagcttatgc agtcaccc 120
 10 tttgaaaatg ttaaatacaa gtcctattct cttgtccag ctgggtttag ctagaggttag 180
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
 gaagtaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tggtagtatct 300
 taaaagtcat ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcatgc 360
 ttactccaaa cccagttaa ttccccactt tttaagtag gcttagctt gaggatgttt 420
 15 tggctataac cgaaatgtaa atccaccc 120
 tactgaaaac aatggtgcca tatgctccaa agacatttc ccaagataac tgccaaagag 540
 ttttgagga ggacaatgtat catttattat gttaggagcct tgatatctct gcaaaataga 600
 attaatacag ctcaaatacgat gttagtaacca agctttctg cccaggaatg aacaaacatc 660
 actacgaaca ttagactaca agaggaaact ttcataatgc atttttcat tcatacattc 720
 20 attcaataaa cattagccaa gctaattgtcc caagccactg tgccaggtat taacaatata 780
 acaacaataaa aagacacagt ctttcctctc aagggtttca gtcttagttagg gaagatgatt 840
 attcattaaa attttgggtt catcagaatc atgaggagct tggtaaaaaat gtaaattcct 900
 gcctatgttc tcagatattc tggttaggtc aggatggaa acccaaaatc aattctttt 960
 acaaacacta aagggtgatc taacacagggc ggtgtgagga cc

25 <210> 15

<211> 280
 <212> DNA
 <213> Human

30 <400> 15

cgaggtgggc caccgtgtc tggctgaga tttttaatg aggattacat tttttttt 60
 ataataattcc tattctaattc tattgtattc ttacaattaa atgtatcaaa taattctaa 120
 35 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
 aactgtattt tgactctcaa tatttaaaca tttaaaaaaa tgtagttagt tggtaagcac 240
 caatcttaac tatttcacctt gcccggcgcc cgctcgagg

<210> 16

<211> 2041

40 <212> DNA
 <213> Human

<400> 16

45 ccccccgcag aactcccccc tggaaatagga tttttaaaac ctttgacaat tagaaatcct 60
 atagaggtta gcattttta ggtaaaaata tggttgcccc tacagggatc atgcaacttc 120
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tggtagttagaa 180
 atacagacac agtgcgtg aagacactaa acaaaaactg aaaagtacta taccttgcata 240
 50 aattttgtta ttgccttctt tagagacttt ataattctta gttgattttc aaggacttga 300
 atttaataat gggtaattt cacaagacgt aaaggatttt taaaaacaa gtattttttt 360
 ttacctctag catcaattttt ttataaaaga atgctaaataa aattacattt tttgttcagt 420
 aaaactgaag atagaccatt taaatgcttcc taccaaattt aacgcagctt aatttagggac 480
 caggtacata ttttcttctg aacattttt gtcagcatg tctaaccata aaagcaaatg 540
 gaatttttaag agtagattt ttttccatg atgcattttt ttaataatg tggtaagaaa 600
 55 ataaaaacaa gcactgagtg tggctcttgc aagtataagg gtctaatgaa aaataaaaga 660
 tagatatttgc ttatagtctg acatttttaac agtcatagta ttagacgtt cgtgaccagt 720
 gcatttttgc ctctctcagg atcaaaatac gagtctggca actgttattaa atcctccctcc 780
 accccctcca ccagttggc cacagcttcc tgggggtcg ttgtcatcaa atccatttggg 840
 60 ccgaaatgaa catgaaggcag atgcagcttgc gaggggccgg gctcgagcat tcaactcttgc 900
 ttctgttaaa tatagtttat tggcttttgc tatacatcc ataagttttt tctgttagagg 960
 tgggtctcca ttatccaga gtccactggt tgggttattt ccacttaaac cattagttact 1020
 atgctgtttt ttataaaaaa gcacataagc tggctcttgc gggaaacctgc tcgtatattt 1080
 ctggactgac tggaaatgaa taaatgtcac tctactgtca ttaataaaaa acccattttt 1140
 ttgacatttc ttatccatc aaatcctgtt caaaaactgc actgggacta tctctccctt 1200
 65 gtaaatgact ctgggaggat gctaattgtcc gggccctcaga ctgggttgc atctgtatg 1260
 aagagtctgtt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtccc tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 cccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560
 5 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gtttctcag cattttgcag agaggcacag ttttcacaat aatattgtt atcaccagta 1680
 agaatctctg gagcccaaaa aataatttag taagtcagtt actgaagggtg tggtttcacc 1740
 tcccggttcc ttaggtacat ctttattaac aagaatcttgc tttagattcgt tagggacaga 1800
 10 agtgtttca gaacagtaaa actcattagg aggactgcct atggttttt cattcacaag 1860
 ttagtcacag atgaaggcag ctgttgttgg attataaaact actggctctt ctgaaggacc 1920
 ggttacagac gcttgcattt gaccaccatc ttgtatactg ggtgatgatg ctggatctt 1980
 gacagacatg tttccaaag aagaggaagc aaaaaacgca agcgaagat ctgtaaaggc 2040
 t
 15 <210> 17
 <211> 235
 <212> DNA
 <213> Human
 20 <400> 17

 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgttagtctc 120
 25 agatactcag gagactgagc tgaaaaggat cacttgagcc caagaagttc aaggttacag 180
 tggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

 <210> 18
 <211> 2732
 <212> DNA
 30 <213> Human

 <400> 18

 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 35 tcatgttcat aactactta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttggta tcacattgtg caaaatggtg aagcattcaa acactttgaa 180
 accagattct agcaggttgg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggccctcacct ggtcctttgg gttgctttt attaatgagg agactattgt 300
 40 gatggcatat ctcttcacta tatttaatgc tttccagggta gtgttcattt tcattttca 360
 ctgtgctctc caaaagaaaag tacgaaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggaggc ctcccaactg agagtccccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgctcgc tattcctctg gcacacagag tcgtataaga agaatgtgga atgatactgt 540
 gaaaaacaa tcagaatctt cttttatctc agtgacatc aatagcactt caacacttaa 600
 tcaagggtggc ataaatctta atatattttt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagt 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgctttg 840
 agaaaatgt catttcagaa tttagtgcaca acaacttacg gggcagcagc aagactcaca 900
 50 acctcgagct cacgctacca gtcaaaccctg tgattggagg tagcagcagt gaagatgatg 960
 ctattgtggc agatgcttca tctttatgc acagcgacaa cccagggtcg gagctccatc 1020
 acaaagaact cgaggccacca ctatttcctc agcggactca ctcccttcg taccacccccc 1080
 agaagaaaatgtaa gaagtcccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtcccccc aacagagact ctctttatc aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agccctgaca tggaaagaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacattttac tataaaagca tgccaaatct tggagctggc catcagctc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatggta tataatcccc attaacaaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaat gcagctggta acaagtctt 1440
 aatcatacag ctaaggaatt ccaagggcca catgcagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgggttctc 1560
 60 tgggttaaaa aagatgactg aaccttgcag ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgtatatac acacagagta tactaaagtg aattattgt tacaagaaaa agagatgcca 1680
 gccaggtatt ttaagattct gctgctgttt agagaaattg tggaaacaagc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatctg tgggacaaat 1860
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagat tctgcattcag 1920
 tttgcagttc actgcaaatc tttacatta aggcaaagat tggaaaacatg cttaaccact 1980

5 agcaatcaag ccacaggcct tatttcataat gtttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatattttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaaact gaaatataat tgtcattaaa ataattttaa agagtgaaga aaatattgtg 2160
 aaaagctctt ggttgcacat gttatgaaat gtttttctt acactttgtc atggtaagtt 2220
 ctactcattt tcacttctt tccactgtat acagtgttct gcttgacaa agttagtctt 2280
 tattacttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgtat gaaatctaga aaagattgtg 2400
 tgtcaccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcacaaac 2460
 tttctagtga acaaaagggtg cctattctt tttaaaaaaa taaaataaaa cataaaatatt 2520
 actcttccat attccttctg cctatattta gtaattaatt tattttatga taaagttcta 2580
 atgaaatgtt aattgtttca gcaaaattct gctttttt catcccttg tgtaaacctg 2640
 ttaataatgtt gcccattcact aatatccagt gtaaagtttta acacggttt acagtaaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaaa aa

 15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

 20 <400> 19

 25 ctccctaaat gattttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgcctt gcatatttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gcttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

 30 <210> 20
 <211> 2361
 <212> DNA
 <213> Human

 <400> 20

 35 attgtaccag cttgtatgaa cgtggccct gttcgctt tgagggccat aagtcattt 60
 cccactggtt tagaggctac cttatcattt tctccgtat ccggaaagggt tctcccaagt 120
 cagagtttac cagcaggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgttagtggat gtgcttgctg 240
 agtggggctc cctgtacgtg ctgacgcggg atggcgggt ccacgcactg caggagaagg 300
 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgatataacc 360
 ttgccaagag ccagcatctg gacagtgtat ggctggccca gattttcatg cagtagggag 420
 accatctcta cagcaagggc aaccacgtat ggctgtcca gcaatataatc cgaaccattt 480
 gaaagttgga gccatcctac gtatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccac cataccaccc 600
 tgctcctcaa ctgtataacc aagctcaagg acagctcgaa gctggaggag ttcatcaaga 660
 aaaagagtga gagtgaagtc cactttgtat tggagacagc catcaaggatc ctccggcagg 720
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtggtacc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ctttcgatac atcggcaagc 840
 tgcctttga gcagggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900
 taccagagca gacaactcaat ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgatagggag gccccaggct gcagggccaa ctctgaggag ttcatcccc 1020
 tctttgccaat taacccgcga gagctgaaag ctttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccagggatc tacgacacac tccttgagct gcgactgcag aactggccc 1140
 acgagaagga tccacaggat aaagagaagc ttcacgcaga ggcattttcc ctgctgaaga 1200
 gtggtcgtt ctgcgacgtc tttgacaagg ccctggcct gtgccagatg cacgacttcc 1260
 aggatggtgt ctttacatt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcaggatca tcagcgtgtg tgagcgccat ggggagcagg 1380
 acccctcattt gtgggagcag gcccctcagct acttcgtcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgccca cctcttctag 1500
 tggtgcagac cttggcccac aactccacag ccacacttc cgtcatcagg gactacctgg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggt 1620
 accgagagga gaccaccgt atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680
 tttccaaaaa gaccaagtgc agcatctgtt acagtgcctt ggagttgccc tcagtccact 1740
 tcctgtgtgg ccactccttc caccaacact gctttgagag ttactcgaa agtgcgtcg 1800
 actgccccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gcccaggaac 1860
 aqaaacqqaq tctccatqat caattccaaq atcaqctcaa qtqctccaat qacagcttt 1920

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctccccacagc cagactgacc tccagcctgg aggctggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 5 agaacagaca caatgggacc tggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 gctccactct catctaatgt cacagccctc acaagactaa agcggaaactt tttctttcc 2220
 ctggccttcc ttaattttaa gtcaagctt gcaatccctt cctcttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttggaaaaaaa aagctggttt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21

aggtgttaga tgctcttcaa aaagaaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 20 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc
 <210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22

tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agataacaaca 60
 30 caaatgttcc agtttagaagg aattcaaaacg gaatgccaag gtccaaagcca gctcaagaa 120
 ataaaaaggg agtttggag taatagataa gatgactcca atactcaact ttcctaaggg 180
 caaaggtaact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccaccat 240
 taccatagtt caaacaggca agttatggc ttaggacac tttaaaattt gtgggtggaa 300
 tagggtcatt aataactatg aatatatctt tttagaaggtg accatttgc actttaaagg 360
 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 35 gggagctgga agagccttgg aagtttctat tacaaataga gcaccatatac cttcatgcca 480
 aatctcaaca aaagctctt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540
 gtctgaccag ttcttggtaa caaacatatac tttgtgtgtc tttgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaaa 660
 40 ggcagggctc cctaattgtcc attattacat ttccattccg aatgccagat gttaaaagtg 720
 cctgaagatg gtaacccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780
 aaacaacagt agaaaagaagg ggcaactt gctgcagag acaaagttag tttttttcg 840
 ccatggattt cagtcctctc ctccagacca gctgcttatt tcctcagggg cccagggaaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23

ggtctcttct ttccaaaaat ttttccaaa agtgttctt tatttcagtg aacatataatt 60
 gtataaaatac tctatttat atgcacttcc acaaaaagcga tataatttaa aagttttttt 120
 55 cattagaaat aaatgtataa aaataaaatat gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgttaatt tatagttaaca 240
 tattttacta tatacatatg gaaaaaatca tatttcacca gaagagctga acagacattc 300
 accaggatac gactgttggc ccagctgctg gagatggacc tgctaccctc cagcagcctc 360
 cccaccacaa gacaagtgtat ctaatgtcc ccaaaccctgt gggaccctgt tctacacacc 420
 tcattttgt tccggcggtt catcctcattt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaagggaaat 540
 tggaggtact aagctcattt gttctcctt agcttttacc agcatctaat gtttcactgc 600
 ttttttcca ttgttagactt taatgcactt gaataaaatac atggagttgt tttttcctca 660
 aaatgaattt cacaataaa gactgagatg gtccaaaaaaa ggaaagagga agccatttgc 720
 gttatttcac gttgctgagc ctccctctca ttttgcacaa tctgaagttt taattctcgg 780
 65 tagaaataat gtataaaacat tctctgaaac catagcagcc ataaacagtg ctggtcaaag 840
 atcctatttg tactccttcc tccccccattt gtttagtggg taaagtaaaa caggtcttag 900

5 taaaatctca ctttctcct actttcatt tcccaacccc catgatacta agtatttgat 960
 aagtaccagg aaacaggggt tgaatagtt ctaactttt ttgacaattg ctttgtttt 1020
 tctaaactg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgcataatca ctgctcagag gtaataatc ctcactaact atcctatcaa atttgcaact 1140
 10 ggcagttac tctgatgatt caactcctt tctatctacc cccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttccctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgttttagg tttctttaaa ggatcacagc 1380
 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt ttttgtAAC 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgcccactgg gggcagggat 1500
 ggtctgcaca aggtctggtg ctggctggct tcacttcctt tgcacactcg gaagcaggct 1560
 15 gtccattaaat gtctcggcat tctaccagtc ttctctgcca acccaatca catgacttag 1620
 aacattcggcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaaggca ttgcccacag 1740
 taagaacctg gatggtcaag ggctcttga gagggctaaa gctgcgaatt cttccaatg 1800
 20 ccgcagagga gccgctgtac ctcacagacaa cacctttaa cataatgtct tgctctaagg 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagcttg atggcaagaa 1920
 agtgcattt gttcctggat ccctctggt tccgctgtt cacttcgatg ttggggctc 1980
 cagttggaaat tggatgata tcacatgatc cagggtttgc actagtaact gatcctgata 2040
 ttttttaca agtagatcca ttccccccgc aaacaccaca tttatcaaac ttcttttgg 2100
 agtctatgat gcgatcaca ccagcttta caca

25 <210> 24
 <211> 1626
 <212> DNA
 <213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatataattt tgctttaaaa tatattttgg 60
 ttatTTGAA tacagacatt ggctccaaat tttcatctt gcacaatagt atgactttc 120
 actagaacctt ctcacacattt gggaaactttg caaatatgag catcatatgt gttaaggctg 180
 tattcattaa tgctatgaga tacattgtt tctccctatg ccaaacaggt gaacaaacgt 240
 35 agttgtttt tactgataact aaatgttggc tacctgtat tttatagttt gcacatgtca 300
 gaaaaaggca agacaaatgg cctcttgcac tgaataacttc ggcaaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgttagagc ttgcgttagaa tggattacat 420
 ggttagtgatg cactggtaga aatggttttt agttattgac tcagaatca tctcaggatg 480
 aatctttat gtctttttat tggatgata tctgaattta ctttataaag atggtttttag 540
 40 aaagctttgt ctaaaaaattt ggcttaggaa tggtaacttc atttcagtt gccaagggt 600
 agaaaaataa tatgtgtgtt gttatgtta tggtaacata ttatttagta ctatctatga 660
 atgtatttaa atatTTTCA tattctgtga caagcattt taatttgcAA caagtggagt 720
 ccatttagcc cagtggaaa gtcttggAAC tcaggttacc cttgaaggat atgctggcag 780
 ccatctctt gatctgtgt taaactgtaa ttatagacc agctaaatcc ctaacttggA 840
 tctggaatgc attagttatg cttgtacca ttcccagaat ttcaaggggca tcgtgggtt 900
 45 ggtctagtgA ttggaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tggatcatg 1020
 aaacttagta gaggggattg tggatTTTT atacaaattt aatacaatgt cttacatgt 1080
 taaaattctt aaagagcaaa actgcatttt atttctgtat ccacattcca atcatattag 1140
 50 aactaagata ttatctatg aagatataaa tggtgagag agactttcat ctgtggattg 1200
 cgttggTTCT taggggtcct agcactgtat cctgcacaag catgtgatat gtggaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggatc tgcaatcaca 1320
 atGCCAGATG gtgtttatgg gctatttggtaa tggatgtg tggatgtct atgaaagtaag 1380
 tggatTTGTT ttcatctt gggaaactctt gatgtatgt ctttggatgtt gataaaattt 1440
 tggatgtcattt caactttgca ttggatgtt gtttggatgtt atttataatgt 1500
 attatacctg tcacgcTTCT agttgttca accattttt aaccattttt gtacatattt 1560
 tacttgaaaa tattttaaat gggaaatttaa ataaacattt gatgttac ataaaaaaa 1620
 aaaaaaa

60 <210> 25
 <211> 1420
 <212> DNA
 <213> Human

<400> 25

65 gttcagcatt gtttctgctt ctggaaatctg tatagtacac tggtttgtaa tcattatgtc 60

5 ttcattgaaa tccttgctac ttctttcct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttgaaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtggggaaaaa ctttaagagt ttccacatat tagtttcat ttttgagtc aagagactgc 300
 tccttgtact gggagacact agtagtatat gttgtatg ttactttaaa attatcttt 360
 tattttataa ggcccataaa tactggtaa actctgttaa aagtgggcct tctatcttgg 420
 atggttcac tgccatcagc catgctgata tattagaaa ggcatcccta tctacttact 480
 ttaatgctt aaattataca taaaatgctt tatttagaaa acctacatga tacagtggtg 540
 10 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 agggtgaga aagaggtact ggaaaacatg cagatgagga tatctttat gtgcaacagt 660
 atcccttgca tgggaggaga gttactcttga aaggcaggc agcttaagtg gacaatgtt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgcctgaa gtttagtat ttgtttcta ggtggaccc tcggaaaaccaa 840
 15 accagtaccc ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900
 tgtatttcc tccagagatt ttgaacttta ataattgcgt gtgtgtttt tttttttaa 960
 gtggctttgt tttttttctt caagtaaaat tttgttgcata tttcctttat aggggcagg 1020
 catgagttag ggagactgaa ggttattgtt gactgtacat gtgccttctt aatgtgttcc 1080
 tcgacacatt tttttcagt aacttggaaa ttcaaaaggg acatttggtt aggttactgt 1140
 20 acatcaatct atgcataaaat ggcagcttgc tttcttgagc cactgtctaa attttgtttt 1200
 tatagaaatt ttttatactg attggttcat agatggtcag tttgtacac agactgaaca 1260
 atacagcact ttgccaaaaaa tgagtgtacg attgtttaaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttggg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaaataaa gtgccttta acttcaaaaaa aaaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

aaacaaacaa aaaaaaaagg agtactgtat atgtaaatac tagctttca atgtgctata 60
 caaacaatta tagcacatcc ttccctttac tctgtctcac ctcctttagg tgagtacttc 120
 35 cttaaataag tgctaaacat acatatacgg aacttggaaag ctttggtagg ctttgcctt 180
 ggtaatcagc ctatgttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
 cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg ggcgtactgt 300
 cattggggc caggtgattt ttcccttgcaa gggctgtcct gtacctgccc gggcgccgc 360
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agtctggct gccctcagga 420
 40 attccaaatg accgaaggaa caaagcttca ggctctggg tgggtctcc cactattcag 480
 gaggtggtcg gaggttaacgc agttcattt cgtccagtc tttccagtt taaaagtgt 540
 tgtaagatg ctgcattttaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtggaga 660
 cacacccaga gcctgaagtt tgccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

tcccagcggc atgaagtttgc agattggcca ggcctgtac ctgggcttca ttccttcgt 60
 ccctctcgct cattgggtgc accctgtttt gctgtcctg ccaggacgag gcaccctaca 120
 55 agccctaacc caggccccgc ccaggccac caagaccact gcaaacaccg cacctgctt 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240
 ggttacagggc tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
 tgggctgggtt cccggcgaaa ctgtcaatgg aggcagggtt tccagcacaagtttacttc 360
 tggcaattt ttgtatccaa gaaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 ggacagaggg gggaaaataaga ggaggagaaa gctcttata ccaaagactg a

60 <210> 28
 <211> 929
 <212> DNA
 <213> Human

65 <400> 28

5 ggtgaactca gtgcattggg ccaatggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctggtggg cttccccc actgtcattt gaggcatctt 120
 tggaaagaac aacgccagcc ccttgcgtgc accctgtcgc accaagaaca tcgccccggga 180
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgtt gaggcttccct 240
 gccttcagt gccatctctg tggagctgtt ctacatctt gccacagtat ggggtcggga 300
 gcagttacact ttgtacggca tcctcttctt tgtcttcgcc atcctgtga gtgtggggc 360
 ttgcattctcc attgcactca cctacttcca gttgtctggg gaggattacc gctgggtgg 420
 gcgatctgtg ctgagtttgc gctccaccgg cctcttcattt ttctctactt cagtttctt 480
 ttatgcccgg cgctccaaca tgtctgggc agtacagaca gtagagtct tcggctactc 540
 cttactcaact ggttatgtct tcttcctcat gctgggcacc atctcctttt tttcttcctt 600
 aaagttcatc cggtatatact atgttaacctt caagatggac tgagttctgt atggcagaac 660
 tattgctgtt ctctccctt ctcatgccc tggtaactc tcctaccagg ttctcttctt 720
 15 attgactgaa ttgtgtatg gcattgttgc ctccctttt tccctttggg cattccttcc 780
 ccagagaggg cctggaaatt ataaatctt atcacataag gattatataat ttgaactttt 840
 taagttgcct ttatgtttgg tcctgatttt tcttttaca attacaaaaaa taaaatttt 900
 taagaaaaaa aaaaaaaaaa aaaaaaaaaa

20 <210> 29
 <211> 1775
 <212> DNA
 <213> Human

25 <400> 29
 25 gaacgtgatg ggaactttgg gaggatgtct gagaaaaatgt ccgaaggat tttggccaa 60
 accagaaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
 30 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaaagc caccgctggt acaggttagac cagaaacacc acgtcgccc ggaagcaggc 300
 cagccggta gacgtggca tggtgatgat gaaggcaaaac acgtcatcaa tgaagggtt 360
 gaaagccttg taggtgaagg cttccaggg cagatgtgcc actgacttca acttgttagtt 420
 cacaagagc tggggcagca tgaagagggaa accaaaggca tagacccgt tgacgaagct 480
 gttgattaac caggagtacc agctttata tttgatattt cttttttttt aggagtgaat agacagcacc 540
 35 cccgacacag agagggtaca gcaggatgta caagtacttc atggccttag tatcgactc 600
 ctcggttttc ctctcagatt cgctgttaat gccaaactga aattcgggca tcaggccct 660
 caaaaaaaaata gtcatcttca atgccttctt cactttccac agctcaatgg cggctccaa 720
 acccgccggg accagcacca gcaggctcg tgcctcgcc agcaggaaca gaaagatgac 780
 40 cacggtgctg aagcagcgcc agagcactgc cttggtgac atgcccatttca tgctcttctt 840
 cttcttccag aaactgtatgt cattttaaa ggccaggaaa tcaaagagaa gatggaaacgc 900
 tgcgacaaag aaggctcagcg ccaggaagta taagttgtt tctttttttt ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gactacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gccccagtgaa gaccttgcgt taggacacgg tgagggcag 1080
 45 ctcggtggtt gagggttta tgaccatcag gtccttcacg cggttgtgtt gctgggtcgat 1140
 gaacaggatg ggcaggtaat gcacggttt ccccgctgg atcatcttca tgtaccgtt 1200
 cacatcgccca ggcaggagg acccgtaaa gacaaagttt tccgccccatca cgttcagcgc 1260
 cagccgcgtt cgccagggtt acactggctc atccaggca ctcgtcggtt tcttctccgc 1320
 ctcgatctgc tggatgtatcacttccggt gagggtt gacttcttctg gcttggggac 1380
 catgttaggtt gtcagaggac tgaccaggatg cacctgttcc cgtcgtgtcc acggcaggac 1440
 50 cccagcgtga tggaggaaga tgtaggatcata cagcgtccca ttgtttctcg ttttctttgg 1500
 tacagaaaca ttaactgtcc ttcaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggatcg atgttgcgtt cagcaccagg gtgggaccc gtcgtgtgtt acacgctcag 1620
 ctgcagcttgc gggccggccgg ccaggatggg ctggatgcgtt ttggcgtcgc cggagcacgg 1680
 55 gccccgtttag acgatgcgtt acatgacca gcagggtgtc accacgtaga ccacgaacac 1740
 gcccaccacc aagctggta aggagctgcg gcccc

60 <210> 30
 <211> 1546
 <212> DNA
 <213> Human

<400> 30

65 aaaataagta ggaatggca gtgggttattt acatttacta cacctttcc atttgctaat 60
 aaggccctgc caggctggga gggattgtc cctgcctgtt tctggagaaa gaagatattt 120

5 acaccatcta cgggcaccat ggaactgctt caagtgacca ttcttttct tctgcccagt 180
 atttcagca gtaacagcac aggtgttta gaggcagcta ataattcact tggtgttact 240
 acaacaac catctataac aacaccaaac acagaatcat tacagaaaaa tggtgtcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcaccatg aattacttaa aatgtctctg 360
 atgtcaacag ctacttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
 gtcaggaaga atgactccat cattcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaca 540
 acagaaatac caggtgtgt tctacaacca gatgcacac cttctaaaac tggtacatta 600
 acctcaatac cagttacaat tccagaaaaac acctcacagt ctcaagtaat aggcaactgag 660
 ggtggaaaaa atgcaagcac ttcagcaacc agccggctt attccagttat tattttgccg 720
 gtggttattg ctttgattgt aataacactt tcagtatttgc ttctgggtggg tttgtaccga 780
 atgtgctgga aggcaagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900
 gcacaaggaaa aaaccaagaa ctgacagctt gaggattct ctccacaccc aggcaataat 960
 tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccgact tccatacctg ctgctggact gtaccagacg tctgtcccg taaagtgtatg 1080
 tccagctgac atgcaataat ttgatggaaat caaaaagaac cccggggctc tcctgttctc 1140
 tcacattaa aaattccatt actccattta caggagcggt ccttagaaaaa ggaatttttag 1200
 gaggagaatt tgtgagcagt gaatctgaca gcccaggagg tgggctcgct gataggcatg 1260
 actttcccta atgtttaaag tttccgggc caagaatttt tatccatgaa gactttccta 1320
 ctttctcggt gttcttata ttacctactg ttgttattta ttgtttacca ctatgttaat 1380
 gcagggaaaaa gttgcacgtg tattattaaa tatttaggtag aaatcataacc atgctacttt 1440
 gtacatataa gtattttatt cctgcttgc ttttactttt aataaataac tactgtactc 1500
 aatactctaa aaatactata acatgactgt gaaaatggca aaaaaaa
 25 <210> 31
 <211> 750
 <212> DNA
 <213> Human
 30 <400> 31
 35 cacttggca cccccatttt ctaaaaaaaat ggaaatctgg agggcaaaaaa aggtgtgctg 60
 aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120
 atagcaaatg gatcctttt ggcctccctt ggagcatgcc ttccctatct tatccttggc 180
 cccactaaag cagaacgtta cggatatttc tggtttgcc attggatgcc tatctggcca 240
 aacagcctt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300
 tgtacatgct tgctcattac aatttgaca tttttacat agtgaagacc ccaaacatat 360
 cagtgaaaca tgacaagatc ataaagaaca gtatcatatt attatttagt cgctttaca 420
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaaattcac tgagttatac 480
 ttttaatagc ttcctcagca cactattcc catgcattaa atatgataaa ataatctatc 540
 actgcccattc ggtcttgtaa aaaggaagtc tgaatacaga gcccacaaca ctaaaattgt 600
 ttttctagct acaaagtata gcatcatcaa cacagacacg atttggactc cctgacaggt 660
 ggattggaaa acggtgttt aagagaagag aacattttaa cataaatgtc attaagaatc 720
 45 ccaaaggcct tatttgcac caccgtcccg
 <210> 32
 <211> 1620
 <212> DNA
 <213> Human
 50 <400> 32
 55 gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggatgca 60
 gtgcagccat tcataagaac cttgggtccc cagaaaaatc tgcctttt ggtaccaaac 120
 ctgaggtctt ttggaaagata atgtagaaaaa ccactaccta ttgaaggcct gttttggcta 180
 atctgtcaa actctgatga tacctgcctt atgtggattc tttccacac tgcttcatt 240
 ttttaagtata aagacttaga aaactagaat aatgtttta caaataatta aaagtatgtg 300
 atgttctggg tttttcctt ctttttagaa cccgcctcc attaaaaaaa ttaaaaaaaaa 360
 aaaaaaaaaact tttaacattt aaaaaataaa aattaacaaa attcactta ttccaggaca 420
 cgctggcatt tggactcaat gaaaaggca cctaaagaaa ataaggctga ctgaatgtt 480
 tccataattt tcacacaaata acagtcctt tctatccagc ttgccttcca tttatctcta 540
 gggtagctt ttcaggcaac atccttggtc attgccaga aagtacgtga gctatcagtg 600
 attggaatgg cacagggaaac cgaatcacat gggtgcctc cccttggtt tcaagtatct 660
 tggagttgtg cacaaaaaatt agtcatgcc ttcatgtct tttttttttt acctaccctt 720
 tgacaatcag gtqctaattga ttgtataacta ttaaaaccag cacataaqta ttgttaatgt 780

5	gttttcctcc	tagttggaa	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tctttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagttcag	gttggcatg	atcatcattc	tcgatgat	tctcactttg	960
	tcgcaaatct	gcccttatacg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcaagcatta	taagacctt	gtgccagaa	1080
10	aaatctgtcc	ttttggta	caaaccctgag	gtctttgga	agataatgt	gaaaaccact	1140
	acctattgaa	ggcctgttt	ggctaattctg	tgcaaactct	gatgatacct	gcttatgtgg	1200
	attctttcc	acactgctt	catttttaag	tataaagact	tagaaaacta	gaataatgct	1260
	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttctttt	agaaccctgt	1320
	attaaacaa	gccttcttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtattt	tgttccta	tttaaaaagc	1440
	tttatgtata	ctctataat	atagatgcat	aaacaacact	tcccctt	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	aggattat	atatataat	1560
15	acatataac	ctttgttaacc	tttatactgt	aaataaaaaaa	gtgcttt	tcaaaaaaaa	1620
	<210>	33					
	<211>	2968					
	<212>	DNA					
20	<213>	Human					
	<400>	33					
25	aaaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	ggaaagacat	tagataaaaaa	gccaaataaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaaggggct	tatgacaaag	caaaacggag	gattgagaaa	300
30	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
	gtacttggc	atgtggacac	aggaaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	ttgtatcaca	caacaaattt	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttt	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
35	ggaagctctc	tttgtgacat	tgccattttt	gttgttata	ttatgcatgg	tttggagccc	660
	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaat	gtcccttcat	tgttgcactc	720
	aataagattg	ataggttata	tgattggaaa	aagagtctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttggagg	agcgagcaaa	ggcttatttt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttttttt	atgagaataa	agatccccgc	900
40	acttttgtgt	ctttggtacc	tacctctgca	catactgg	atggcatgg	aagtctgatc	960
	taccttcttg	taggttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tggcaccac	tatagatgtc	1080
	atcttgcata	atgggcgttt	gaaggaagga	gatacaatca	ttgttcctgg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctcctc	ctatgaagga	attacgagt	1200
45	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	aggggtaaa	gattcttgg	1260
	aaagacctgg	agaaaacatt	ggctggttt	cccttcctt	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttt	agctctactg	1440
	gaatttctga	aaacatcaga	agtccctat	gcaggaatta	acattggccc	agtgcataaa	1500
50	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaatttt	1560
	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttga	1620
	atttttagtg	cagaaattat	ttatcattt	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tattccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcg	gatccgatag	tgatgggggt	gacggtggaa	1800
	gcaggtcagg	tgaaacaggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgcacatc	1860
	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
55	gaagtttgtg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatgtt	tggaaagacat	1980
	tttgaagcta	cagatattct	tgttagtaag	atcagccggc	agtccattga	tgcactcaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttggaa	tcatctaatt	tttcacatg	gagcaggaac	tggagtaat	gcaataactgt	2160
	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtattt	gacactgatg	2220
60	gacttaagta	tggaaggaag	aaaaatagg	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgcacag	tggtcagtt	catgtcccc	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttccccca	acccttctct	acttggctgc	tgtttaaag	tttgccttcc	2400
	cccaaatttg	gatttttatt	acagatctaa	agcttttgc	attttatact	gattaaatca	2460
	gtactgcagt	atttgattaa	aaaaaaaat	gcagattttt	tgattcttgg	gactttttt	2520
65	acgtaaagaaa	tacttcttta	tttatgcata	ttcttcccac	agtattttt	ccagcattct	2580
	tctgccat	gcctttaggg	ttttataaa	ataqaaaatt	aqcattctq	atatttctt	2640

5 agctgctttg tggtaaacca tgggtaaaaa gcacagctgg ctgctttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaaacaga 2760
 catccaccag taagcaagct ctgttaggtt tccatggta gtttagctt ctctccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactaccct 2880
 ggtatgccag cacctggta acagtaggag atttataca ttaatctgat ctgtttaatc 2940
 tgatcggtt agtagagatt ttatacat

<210> 34

10 <211> 6011

<212> DNA

<213> Human

<400> 34

15

20 acggggcgcc ggacgaccgg cacatcttat cctccacgcc ccactcgcac tcggagcg 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggcc 120
 cggcttgagc cgagcgcagc acccccccggc ccccgccca gaagtttggt tgaaccgggc 180
 tgccgggaga aacttttttc tttttccccct ctctcccggtt agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctcgtgggtt cgggttcggc cggccgcaga agggggcg 300
 tccgcccggc aggggaggcg ccccccggga cccgagaggg ggtgaggac cgcgggctgc 360
 tggtgccggc gcccgcagcgt gtcccccgcg caggggaggc gccgccccgc tcccgcccg 420
 gctgcgagga ggaggcgccg gggcgccagg agatgtact tggtgccggg ggacaggggg 480
 ttggccggct gcccccacct cctggctctg ctgctgggc tgctgctgt gccggcgcc 540
 tccggcaccc gggcgctgtt ctgcctgccc tggacgagt ccaagtgcga ggagcccaagg 600
 aaccggccgg ggagcatcg tgcggctgtt gtcacacgtg cgccagccag 660
 30 gggaaacgaga gctgcggcg caccccccggg attacggaa cctgcgaccg ggggctgcgt 720
 tggtcatcc gccccccgtt caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780
 gaagatgaga actggactga tgaccaactg ctgggtttt aaccatgcaaa tgaaaacctt 840
 attgctggct gcaatataat caatggaaa tggatgtt acaccattcg aacctgcagc 900
 aatccctttt agtttccaag tcaggatatg tgcctttcag cttaaagag aattgaagaa 960
 gagaagccag attgctccaa gggccgtgtt gaagtcagt tctctccacg ttgtcctgaa 1020
 35 gattctgttc tgatcgagggtt atatgtctt cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctatgtcaa aagcctcagg gaagccggga gagtgtgtt acctctatga gtgcaaacc 1200
 gtttccggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 40 ccggacagct atgaaaactca agtcagacta actgcagatg gttgctgtac tttgccaaca 1320
 agatgcgagt gtctctctgg cttatgtgtt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctgcgtggca tggacacccctt gggaaagtgtt gtatgtctt tgaatgtgtt 1440
 aatgatacaa agccagccctg cgtatataac aatgtggaa attatgtatgg agacatgttt 1500
 cgaatggaca actgtcggtt ctgtcgatgc caagggggcg ttgccatctg cttcaccgccc 1560
 45 cagtgtggtg agataaaactg cgagaggta tacgtccccg aaggagatgtt ctgcccagt 1620
 tggtaagatc cagtgtatcc ttttataat cccgtggct gctatgcaaa tggcctgatc 1680
 cttgcccacg gagaccgggtt gccccggac gactgcacat tctgccagt gtcacagg 1740
 gaacgccact gcgttgcgac cgtctgcggc cagacctgca caaaccctgt gaaagtgcct 1800
 ggggagttt gcccgtgtt cgaagaacca accatcatca cagttgatcc acctgcattgt 1860
 50 ggggagttt caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgt 1920
 cacaatggtt gtcggacctg tcagtgcata aacacccagg aactatgttca agaacgtaaa 1980
 caaggctgca ctttgcactg tcccttcgggtt cccttactg atgccccaaa ctgtgagatc 2040
 tggatgtgcc gcccaggcc caagaagtgc agacccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgtt gacatctgtc gctgtaaagaa atgtccagag 2160
 55 ctctcatgca gtaagatctg ccccttgggtt ttccagcagg acagtacccg ctgtcttac 2220
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tcctgtccgg cacttgcctc 2280
 accgtggatg gtcatcatca taaaaatgag gagagctggc acgtatgggtt ccggaaatgc 2340
 tactgtctca atggacgggaa aatgtgtgcc ctgatcacct gcccggtgcc tgcctgtggc 2400
 aaccccacca ttccccctgg acagtgcgtc ccatcatgtc cagatgactt tgggtgcag 2460
 aagccagagc tcagtactcc ctccatttgc cacgccccctg gaggagaata ctttgcggaa 2520
 60 ggagaaacgt ggaacattgtt ctccgtact cagtgacactt gccacagccg acgggtgt 2580
 tggagacag aggtgtgcc accgctgctc tggcagaacc cctcacgcac ccaggatcc 2640
 tgctgcccac agtgtacaga tcaacccctt cggcccttcct tggcccaaa taacagcgta 2700
 cctaattact gcaaaaaatgtt tgaagggatt atattccctgg cagctgatgc ctggaaaccc 2760
 gacgtttgtt ccagctgcattt ctgcattgtt agcgtatgtt gctgttttc tgagtccctgc 2820
 65 cttctgtat cctgtgaaag acctgcatttgc agaaaaggcc agtgttgcctc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtgggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

5	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgcagggcca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcggaaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atataccat	tgagaagaca	3120
	aaccatcgag	gagagggttga	cctggagggtt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
	atcggtccatc	tcccttagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgcctctcta	ttataatagc	attccttattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
	gactgcaaga	aaggaaccag	agtccaggtg	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggcttctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaact	agaatttgtg	cacttgctt	gtggattgta	3660
	ttggatttgt	acttgatgta	cagcgctaaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cactttcct	caagataact	gaccaagtgt	tttcttagaa	3780
	ccaaagttt	taaagttgct	aagatataatt	tgcctgtaag	atagctgtag	agatatttgg	3840
	ggtggggaca	gtgagtttg	atggggaaag	gggtgggagg	gtgggtttgg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggt	aacataaaag	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctgggttgctg	caaagctcag	gcctgaatga	4020
	gcaggaaaaca	aaaaaggcct	tgcgacccag	ctgcccataac	caccttagaa	ctaccagacg	4080
	agcacatcag	aaccctttga	cagccatccc	aggctaaag	ccacaagtt	cttttctata	4140
	cagtcacaac	tgcagtaggc	agtgaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgt	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
	atgtgagcac	tggagcttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
	gaacaccagg	catttccagg	ggcttatatt	cactgtttgt	tgttgctttg	ttctgttata	4440
	ttgttggttg	ttcatacttt	ttgttgaaagc	tctagcttaa	gaagaaaactt	tttttaaaaaa	4500
	gactgtttgg	ggattcttt	tccttattat	atactgattc	tacaaaatag	aaactacttc	4560
	attttaattt	tatattattc	aagcacctt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
	aaacttttagc	aattatagga	gtatttatgt	aactatctt	tgcttcaaaa	aacaaaagta	4680
	tttgtgtgca	tgtgtatata	atatatata	atacatatat	atttatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgtttt	gatcacttac	aaatttttg	aataacacaa	aatctcatc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagat	gtatgtgtgt	gtgtgtgtgt	4920
	gtgtgtgcgc	gcmcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
	attccctttat	taaaatcttc	ctcatttgg	tttgctttca	gttggtttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttctt	ctgcatcact	aatcagctcc	tggattttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttgg	tagatgcct	caaataataac	tgactgtata	ctatactgtt	aactttcaa	5220
	acagccctta	gcactttat	actaattaac	ccatttgc	attgagttt	cttttaaaaaa	5280
	tgcttgg	gaaagacaca	gataccagt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgtgt	aaatacttgg	acagaggttg	ctgaacttta	5400
	aaaaaaaatta	atttattatt	ataatgacct	aatttattaa	tctgaagatt	aaccatttt	5460
	ttgtctttaga	atataaaaaaa	aaaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaggaa	5520
	aaaaagattt	attatcaagg	ggcaatattt	ttatctttc	caaaataaaat	ttgttaatga	5580
	tacattacaa	aaatagattt	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaaagt	tttatcaaaa	aaaattgtag	atgcttgctt	tttgggtttt	5700
	caatcatggc	catattatga	aaataactaac	aggatatagg	acaagggtgt	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttacttttgt	5820
	tcctgttgt	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaaat	agatatatgg	5880
	cacttggagt	gcatcatagt	tctacagttt	gtttttgttt	tcttcaaaaaa	agctgttaaga	5940
	gaatttatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaaa	6000
	aaaaaaaaaa	a					

55 <210> 34a
<211> 1036
<212> DNA
<213> Human

60 <400> 34a

65 mylvagdrgl agcghllvsl lgl1llpars gtralvclpc deskceeprn rpgsivqgvc 60
gccytcasqg nescggtfgi ygtcdrglrc virpplingds lteyeagvce denwtddqll 120
gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
vgfspsrcped svlieqvapp qeccplpsrc vcnpaqclrk vcqqqnlnil vskasqkpqe 240

ccdlyeckpv fgvd crtvec ptvqqtacpp dsyetqvrilt adgcctlptr ceclsglcgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacfnnn veyydgdmfr mdncrfcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 5 ctfcqcvnge rhcvatvcgq tctnpvkvpg eccpvceupt iitvdppacg elsnctltrk 480
 dcincfkrdh ncrtcqcin tqelcserkq gctlncpfgf ltdaqnceic ecrprpkcr 540
 piicdkycpl gllknkhgcd icrckkcpel scskicplgf qqdshgclic kcreasasag 600
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsc cpqctdqfpr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780
 viscfsescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwldldscth 840
 yclqqgtlcs tvscpplpcv epinvegscc pmcpemeyvpe ptnipiektn hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrlh psedssldsi asvvvpiiic lsiliaflfi 960
 nqkkwipll cwyrtptkps slnnqlvsvd ckkgtrvqvd ssqrmlriiae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35
 <211> 716
 <212> DNA
 20 <213> Human

<400> 35

25 gcagtacctg gagtgtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctgggcccgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagcttct 180
 ggaggctgag gaaggcatga agagtggct ccacctgctg gccgactgag aaaagaattt 240
 ccagaactcg gtcctatttt acagatttag aactatggt tcaagaagag aggacggggc 300
 30 ttgagggaat ctccctgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggtctttt taaggctcta aatgtcaggg tctccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggt ttccctccacc cagggttgcac tcagggggat gatctgggtc 480
 ccattctgtt cttaagaccc caaacaaggg tttttcagc tccaggatct ggagcctcta 540
 35 tctggtagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600
 cccccatcca cctaacaggg tgccacagg gattactgag ggttaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttcctt ccacatcaa aaaaaaa

<210> 36
 <211> 395
 40 <212> DNA
 <213> Human

<400> 36

45 ccaataacttc attcttcatt ggtggagaag attgttagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caactttaa acattgcatg tcctttgccca tttactacat 120
 tctccaaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattattt cattggaatc ctttagccta tgtgatattt cttaacttt gcactttcac 240
 50 gcccagtaaa accaaagtca ggtaaccaa tgtcattta caaaatgtta aaaccctaatt 300
 tgcagttcct tttttaaattt attttaaaga ttacttaaca acatttagaca gtgcaaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37
 <211> 134
 55 <212> DNA
 <213> Human

<400> 37

60 ccctcgagcg gccgccccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccctaaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gagtctccat 120
 aaggacacc gtgt

<210> 38
 <211> 644
 65 <212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gagtagagg 60
 cagtggcgct ttagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 ggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatattgg tggccagca atcctcagac gcctcactta gcacaaatga gaaaactgag 240
 gcttggtgaa gtacgaaac ttgtccaaaa tcacacaact tggtaaaggc acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagttt aggagaaaaga 360
 agatgttta tttccagag gccagtcgtc cacatcaatg gcagacagat gaagaaggcg 420
 ttcgcaccgg aaaaatgtac ttcccggta agtaccttgg ccatgttagaa gttgatgaat 480
 caagaggaat gcacatctgt gaagatgtc taaaaagatt gaaagctgaa aggaagttct 540
 tcaaaggctt ctttggaaaaa actggaaaga aagcgtttaa agcagttct gtgggtctaa 600
 15 gcagatggac tcagagggtg tggatgaaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

25 cttttgttt gggttttcca atgttagatgt ctcagtggaa tggcagata tactttgttc 60
 ctatatgtt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
 gcctcccatc taatctctt gatactctt gatatctaact ctgaggagcg atttctgaat 180
 tagccagtgt tttaccaact ttctgtttagg aattgttatta gaataacctt tcttttcag 240
 acctgctcag ttagacatct tggggaaatgtt agtagggaaaa tagacatttgg tggaaaaaac 300
 agcaaaatgtt gaacattaaa aagactcatt caagtatgtt tataaaggc atggaaattc 360
 30 tggcctttt agcaaaatgtt gaagaaaaaaa ttctgctcag cagtattcac tggatgtt 420
 tttttgttt ttacacgaa tggaaaaatgtt atgtgttaatgtt ggtatagatt ttaatcagct 480
 aacagtcaatccagagattt tgatcagcac caattccat agtagtaatgtt attaaaaatgtt 540
 taagaaatac tactacattt aacattataa agtaggttc tggacataac tggaaaaatgtt 600
 atgtttgtt caatagaaat ttgttccac ttgttattttt aacaaaatgtt tcggaaac

<210> 40

<211> 1328

<212> DNA

35 <213> Human

<400> 40

40 acaattttaa aataactagc aattaatcac agcatatcag gaaaaagtac acagttagtt 60
 ctggtagtt ttgttagct cattatgtt agggtcgta agatgtatata aagaacctac 120
 45 ctatcatgct gtatgtatca ctcattccat tttcatgttc catgcataact cgggcatcat 180
 gctaataatgtt atcctttaa gcactctcaa gaaaacaaaaa gggccttttataatgtt 240
 ggtaaaaaaa atccccaaa tattttgcac tgaatgtacc aaaggtgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
 acttccttca cagtggcggtg tctaccacta caaggactgt gcatctaact aataatgtt 420
 50 taagattcac tatatgttcat agttagatgtt gcattttttt aaaaatgcatt agactcttt 480
 ccatccatca aataacttac aggtggcat ttaatacaga tatttcgtat ttccccact 540
 gcttttttatt tttacagcat cattaaacac taagctcatgtt taaggagccca tcagcaacac 600
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
 actcagaact atatttctaa gcctgcattt tcactgtatc ataattttct tagtaatatt 720
 55 aagagacagt tttctatgg catctccaaa actgcgttgc atcactatgtt ttacttgc 780
 ttaattttat gagaaggat tttcatttt aattgtttt gggattactc cacatctttg 840
 tttattttctt gactaatcag attttcaata gagtgttgc aatttttttttgcataaaagc 900
 atggattgtt catatggttt gccagcctat gggtttacag gcattggccca aacatttctt 960
 tgagatctat atttataagc agccatggaa ttccattttt gggatgttgg caatcttaca 1020
 60 tttatagat gtcatatgttca tagttttcat aggtgttttgc taagaactgtt ttgcttcct 1080
 gtgagttaaatctatgttac tactgggacc ctcaagaggtt ataccacttataatgtt 1140
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
 tggaaataag aaaggaagag ctctctgtat tctataatttgc gaaagagaaaaa aaagaaaaac 1260
 65 ttttaactgg aaatgttagt ttgttacttgc tgatcatgaa tacaagtata tattttat 1320
 tggaaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human
5
 <400> 41

aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgttagg caggtAACAT 60
 ttagctctt tcaaaaaagg agagctcttc ttcaagataa ggaagtgtta gttatggtag 120
10 taaccccccgg ctatcagtcc ggatgggtgc cacccttcct gctgttagat ggaagcagcc 180
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
 tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tcctttggg 300
 tgtctttctc ttctccaacc aacagaaaag actgctcttc aaaggtagg ggtcttcattg 360
15 aaacacagct gccaggagcc caggcacagg gctggggcc tggaaaaagg agggcacaca 420
 ggaggaggga ggagctggta gggagatgct ggctttaccc aaggtctcga aacaaggagg 480
 gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
 tgcaatagac cagcctgcaa gaaagacatg tggggatgt acaggcagtg tggccgggtg 600
 gaacaagcac aggccttggc atccaatggc ctgaatcaga accctagcc tgccatctgt 660
20 cagccgggtg acctgggtca attttagctt ctaaaaaggct cagtctcattt atctgcaaaa 720
 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggtatccaa 780
 aatagtctac ggcataccca ccctgaacgt gcctaatttc gtaagctaag cagggtcagg 840
 cctgggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900
 actctgtctt aacagttagcg tggcacacag aaggcactca gtaaataactt gttgaataaa 960
25
 tgaagtagcg atttgggtgtg aaaaaaaaa

<210> 42
 <211> 956
 <212> DNA
 <213> Human
30
 <400> 42

cggacgggtgg ggcggacgcg tgggtgcagg agcagggcgg ctggccactg ccccaaccaa 60
 ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
35 ttgcctgtct aaagccttaa ctaagactcc cgcggggcggc tggccctgtg cagaccttac 180
 tcaggggatg tttacctgtt gctggggaaag ggagggggaaag gggccggggaa gggggcacgg 240
 caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300
 cacgcaccc cacgcccactg ctcggggcggc atgcatttttgg aaccaaaatgc taaaactgagc 360
40 tcgcagccccc cgccgcctcc ctccgcctcc catccgcctt agcgctctgg acagatggac 420
 gcaggccctg tccagccccc agtgcgcctg ttccggctcc cacagactgc cccagccaa 480
 gagattgtcg gaaaccaagt caggccaggt gggcggacaa aaggggccagg tgcggccctgg 540
 ggggaacgga tgctccgagg actggactgt ttttttccatc catcggtgcc gcagcgggtgg 600
 gaaggaaaagg cagatgtaaa tggatgtgtt gtttacaggg ttttttttgc atacccatcaa 660
45 tgaattaaatt cagatgtttt acgcaaggaa ggacttaccc agtattactg ctgctgtgt 720
 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcgggtg accccatcac 780
 tcgcaggacc aaggggggcgg ggactgctgg ctcacgcctcc gctgtgtctt ccctccctc 840
 ctttccttgg gcagaatgaa ttgcgtgcgt attctgtggc cggccatctgc gcagggtgg 900
 ggtattctgtt catttacaca cgtcggttca attaaaaaggc gaattataact ccaaaaa

50
 <210> 43
 <211> 536
 <212> DNA
 <213> Human

55
 <400> 43

aaataaaacac ttccataaca ttttggtttc gaagtctatt aatgcaatcc cactttttc 60
 cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatgtt ttcacccatc 120
 agtgttagct gtcttttatt ttactcttgg aaatagagac tccatttaggg ttttgcatt 180
60 ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttgaa gagcatatga 240
 tctaaataaa gacatttgaa ggtagttt gattctaaa agtaggttaat agccaaatag 300
 cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaatttagaaa aggtgaaaat 360
 attttttcca gatgaaactt gtgcacttc caattgacta atgaaataca aggagacaga 420
 ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480
65 aggtgggtt cccggcacc tggacctggc caggtgggtt tccgtggta accagt

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
 gctccctggg caccaagtcc cagggcaggag cagctgttt ccatcccttc ccagacaagc 120
 tctattttta tcacaatgac cttagagag gtctcccagg ccagctcaag gtgtcccact 180
 atccccctcg gagggaaagag gcaggaaaat tctccccggg tccctgtcat getactttct 240
 ccatcccaagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
 gtgatttccc ttaggcccag gacttgggccc tccagctcat ctgttcccttc tgggcccatt 360
 catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
 15 gactttaccc gattgccctc agtttgggt tgcttattgg gaaagagaga gacaaagagt 480
 tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
 gacaggattg gctcagatga cccctgaggg ctcttccagt ctgaaatgc attccatgat 600
 attaggaagt cgggggtggg tgggtgggt ggcttagttg gtttgaatt taggggcccga 660
 20 tgagcttggg tacgtgagca ggggtgttaag ttagggctcg cctgtatttc tggtcccctt 720
 gaaaaatgtcc ccttcttcag tgtcagaccc cagtcccagt gtccatatcg tgcccagaaa 780
 agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctgg 840
 gcccagtgac ctgggggagc ctggctgca gcccctcaactg gtccctaaa ccttgggtggc 900
 tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagttcca 960
 25 gagttggctg ttagagcctt ctagaggttc agaatattag cttcaggatc agctgggggt 1020
 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
 tgagggacag tttgggtttg ggacttacca ggtgatgtt agatctggaa cccccaagtg 1140
 aggctggagg gagttaaagt cagtatggaa gatagggttg ggacagggtg ctttggatg 1200
 aaagagtgac cttagagggc tccttgggccc tcaggaatgc tcctgctgt gtgaagatga 1260
 30 gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaaggccc ctacctgctg 1320
 ctgggtccct tgttagcacag gagactgggg ctaagggccc ctcccaggga agggacacca 1380
 tcaggcctct ggctgaggca ttagcataga ggatccattt ctacctgcat ttcccagagg 1440
 actagcagga ggcagcctt agaaaaccggc agttcccaag ccagcgcctg gctgttctct 1500
 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
 cctcttgccct cttgtagaat gcaagctctgg ccctcaataa atgcttcctg cattcatctg 1620
 35 caaaaaaaaaa

<210> 45
 <211> 169
 <212> DNA
 <213> Human

40

<400> 45

tctttgctt ttagctttt atttttgtat taacaggagt ctattacac ataggtctga 60
 45 taaaactggc ttatgatctt cagtctgatt ccagtctgc ataactagat aacgtatgaa 120
 ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagttga

<210> 46
 <211> 769
 <212> DNA
 <213> Human

<400> 46

55 tgcaggtcat atttactatc ggcaataaaaa ggaagcaaag cagtattaag cagcgggtgg 60
 atttgcgtt ttcactttt ataaagtgtt acataaaaatg tcataattcc aaatttaaaa 120
 acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
 aaacaaaaac aaaaacaaaaa aacaatgatc tcttctgggt atcacatcaa atgagatata 240
 aaggtgtact aggcaatctt agagatctgg caacttattt tatataaaatg gcatctgtga 300
 60 ccaagagacg ttatgatataa aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
 cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
 ggccagctcc tttcctgata gtctgattct gccttcataat ataggcagct cctgatcatc 480
 catgccagtg aatgagaaaaa caagcatgga atatataaaatc ttaacatcataa aaaaatgttt 540
 tattttgtaa taaaatcaaa tttcccatgg aaaccttcaa aaactttgca gaatgaggtt 600
 65 ttgatataatg tgtacaagta gtaccttctt agtgcagaa aacatcatta tttctgtctg 660
 cctgccttt tggggggaaa aatgaagact atcattgaaa caagttgtc ttcagtatca 720

ggacatgtt acggagagga aaggttaggaa agggtaggg atagaagcc

<210> 47

<211> 2529

5 <212> DNA

<213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
 gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatttcattt ctgactgggg 120
 tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agtgccttg gcagaaggat gaggtggtga gcttgccgag 240
 15 ggtgggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 gccttactta gtcctggca gagggtgagt gggacctac gaggttcaaa atcaaatggc 360
 atttggccag cctggcttta ctaacaggtt cccagagtgc ctctgttggc tgagctctcc 420
 tgggctcaact ccatttcattt gaagagtcca aatgattcat tttccttaccc acaactttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtctt ctctccctcc 540
 20 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 ccagaggccc ctgcaacttt gcggatttcc agaagggtat aaaaagagca ctcttgagtg 660
 ggtgcccagg aatgtttaaa atctatcagg cacactataa agctgggtgt ttcttcctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
 tgaactctgg tggacagg tacaaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccttcatc ttcctcaaga tctttgttc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttccta ccatttgtt gttattgtc gggtagcca ggagcagtgt 960
 ggtggcaaa gtaggagaga ggcccagagg aaagccatc tccttcagc ttgggggtct 1020
 ccagaaagag gctggatttcc tggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tcctacctgc ttggtaccat agtccctcaa taagatttag aggaagaagc 1140
 ttatgaaact gaaaatcaa tcaaggattt gggagaata atttcccctc gattccacag 1200
 30 gagggaaagac cacacaatat cattgtgctg ggctccca aggcctgcc acctggctt 1260
 acaaatcatc aggggttgc tgcttggcag tcacatgctt ccctgggtt agcacacata 1320
 caaggagttt tcagggaaact ctatcaaggc ataccaaaat cagggtcaca tggggtttc 1380
 cccttcctt gccttcat aaaagacaac ttggcttctg agatggtgg tctttgcat 1440
 35 gcagttgggc tgacctgaca aagccccag ttccctgtgg caggttctgg gagaggatgc 1500
 attcaagctt ctgcagccta gggacaggg ctgttgcattt agttattact gcctcgagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcttaa tgcacagtag tcagtctcag 1620
 ctccggcagt attctcggtt gtatgttctc tggcagagag aggcagatga acatagttt 1680
 agggagaaag ctgatggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 40 tgccaggaaa ccaggaagtc attcaaggtt ttctctgagg ccaaagacac tgagcacagc 1800
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggattgaa aggggaacct 1980
 ctctatctga ggagccccca ctggcttccag aagcaactta ccaagggta tttaaagaca 2040
 tgaaaatttc cagaaataacc atttggtgca tccctttgtt tctgtatataa taaactcagg 2100
 45 tgaaattata ctctgacagt ttctctctt ctgccttc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggt gtccatccatg agatgact caatgccaag 2220
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggc 2280
 tcgagttcca aagctctgat gaagaaacaa gactccttga tggatgttactg atcccactga 2340
 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtgg cacgtcacca 2400
 50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatact 2520
 ggggtgtcc

<210> 48

55 <211> 1553

<212> DNA

<213> Human

<400> 48

60 tttttttttt ttttgattt ctggacaat taagctttat ttttcatata tatataatatt 60
 ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacactgac 120
 aaaaccatata atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 65 ctggccaggc ccgttttcca tcccttaagta ccattcttc atttggggcc ttcttaggtt 240
 gggccctga gcttggtttg tagaagtttgc tgcttaatataa aaccatagct ttaatcccc 300
 tgaaggacag tggatgacccatc atcttgcattt gctcccgct gcctttcagt ttacgtgat 360

5 ccatcaagag ggctatggga gccaagtgaa cacggggat tgaggcta at tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttctttt ttttcctcga 480
 gacggagtct cgctgtgtt cccaggctgg agtgcagtgg cacggtctcg gctcactgca 540
 agctccaccc cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 10 caccgtgtt gccaggatgg tctcgtcctg actttgtat ccgcccgcct cggcctccca 720
 aagtgcgtggg attacaggcg tgagccacca cacctggccc cggcacgtat ctttaagga 780
 atgacaccag ttccctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgtg ggggtgcctc 900
 15 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tggtggaagc cagccttgg ggcagggaaac cagtcagag 1020
 aggctacca gctcagctgc tgccaggagc caggtattt cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgctt 1140
 20 ggtgagctt cactcaacgt ggagatgggt gtggactgg ccctgaaaag cggggccttgc 1200
 agggccaagt gaggtcctca gtccttaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgagggggagc aggaggcttc tctctagttcc ctttggaggg tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcagggg agggagctga agtgattcgg ggctaatgcc 1380
 tcagatcgat gtatttctct ccctggcttc ccggagccct cttgtcaccg ctgctgcct 1440
 gcaggaggcc catcttttctt gggagctt ctgacttaac ttcaactaca agttcgctct 1500
 tacgagacccg gggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggtccc agtactctag gaggctgagg cggggaggatt gcttgagccc aggagttgga 60
 tggtgcagtg agccaagatc gcaccattgc cttccactt gggccacgga gcaataccct 120
 gtctcagaaa acaaacaaca aaaagcagaa acgctgaagg ggtcggtta cgggaaaacc 180
 gcctgtcaga acacttggct actcctaccc cagatcagtg gacctggaa tgagggttgg 240
 tcccgggagg ctttctcca agtgttgcc accagacccg ccatggaaac cctggccaca 300
 35 gaaggctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tgggttgag 360
 ggagggtggg gagtgtgca ggtgtgtgt gtgcccgggg ggtgttcatg ggcaagcatg 420
 tgcgtgcctg tgtgtgtgcg tgccctccc ctgcagccgt cggtggtatc tccctccagc 480
 cccttcgcca cttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540
 ccacgtgggtt ttaaggggag accttccct ggacctgggg gtctgcgcgt atctcatgac 600
 40 caggtgctaa atgacccgac atgcatcacc tgccttcga tgaccaacct ccctgtcccc 660
 gtcccgctga cctgcccccg tggcgtctca cggtgatgcc tgctcctgac attgggtgttc 720
 actgttagcaa actacattct ggtggaaat ttcatgtac atgtgtggca tggaaaat 780
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgg 840
 tactttgacc tcttgcctac aacccttcc ttgggtccga ggctggtagc ttgttca 900
 tcagatgggtt gggggcggtt g

45 <210> 50

<211> 338

<212> DNA

<213> Human

50 <400> 50

atgatctatc tagatgccct accgtaaaat caaaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttcccatgt agccaaactt tccaaaaatt 120
 55 catgttctgt ctccatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgc attgtcatca ttccatggcc ttactttccc tctcagcgttcc atttgctaca 300
 gtaagaaact ttctttctt aattcttggt tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

5 ctagcaagca ggtaaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtttg ctagagcaga ggctgattaa acactcagtg tttggctct ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaaca gttaataaga aatgtgcct tgctaactgt 180
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgcct gctccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtca tctgctcgga gacgctcctg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420
 ccccgctcct ctcccccagg aggctccttg atttatggta gcttggact tgcttccccg 480
 tctgactgtc cttgacttct agaatggaaag aagctgagct ggtgaaggaa agactccagg 540
 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gaggagaaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatctg 780
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat ttaaagaaaa ctaaagtcaa 840
 ttgagcggac aacagaagac attataagat ctgtgaaagt gaaagagaaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgaccc tccaaagtcc tacatacctt 960
 ctaggttaaq gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaaat acagttctgt 1080
 cttccaatac ctctggccat cagatgactt taaaaggtac aggagaaaa gtttaagatg 1140
 atgggcaaaa gtccagtgtt ttcagtaaaag tgctaattcac aagttggagg t

20 <210> 52
 <211> 1200
 <212> DNA
 <213> Human

25 <400> 52

30 aacaggact ctcactctat caacccagg ctggagtccg gtgcgccac cctggctccc 60
 tgcaacctcc gcctcccagg ctcaagcaac ttcctgcct cagtcgtct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcattttt tttttgtaga gacagggttt 180
 cgccttctgt ccaggccggc atcatatact ttaaatcatg cccagatgac tttatatacc 240
 aatacaatat atcaggttgg tttaaaaata attgctttt tattat ttttttgcattttt 300
 accaacccttta atgctatgtt aatagttgtt atactgttgc ttaacaacag tatgacaatt 360
 ttggctttttt ctttgttattttt tttttttttt tttttttttt ttgtgtggc tttttttttt 420
 ttctcagtgtt tttcaattcc tccttggtt aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcattttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 atatgttagtg aaagttatgg tacagtggaa agagtagtttgg 600
 tttcaagaaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggctc 660
 tgctactaat tagctataat ctttgcacaa attacatcac ctttgagtct cagttgcctc 720
 acctgtaaaaa tgaaagaact ggatactctc taaggtcact tccagccctg tcattctata 780
 actctgttat gctgaggaag aaattcacat tttttttttt tttttttttt tttttttttt 840
 gattattaaa gtggaaaaaa gccaattgct tctcttagaa agctcaacta aatttgagaa 900
 gaataatctt ttcaattttt taagaattta aatattttt tttttttttt tttttttttt 960
 45 agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtgatc tccctgcctc tgcctccaga gtagctgcga 1080
 ctatggccat gtgccaccac gcctggctaa catttttgcattttt gacccattttt tttttttttt 1140
 ttttatatctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1200

50 <210> 53
 <211> 989
 <212> DNA
 <213> Human

55 <400> 53

60 aagccaccac tcaaaaacttc ctatacattt tcacagcaga gacaagtgaa cattttttttt 60
 tatgcctttc ttcctatgtt tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggtcactg tgcaggagtc cagggagcct ctacaaatgc 180
 agagtgactc tttaccaaca taaaccctag atacatgcaaa aaagcaggac ctttcctcca 240
 ggaatgtgcc atttcagatg cacagcaccc atgcagaaaa gctggaattt tccttggaaac 300
 cgactgtgat agaggtgctt acatgaacat tgctactgtc tttttttttt ttttgagacag 360
 gtttcgcttg tgcccaggct gagtgcattt cgtgatctca ctcactgcattttt tttttttttt 420
 agttcaagc atttcctgc tcagcctcct agtagctggg ttacaggac tgccaccatg 480
 ccggctaatt ttgttattttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 cccaacctca qtqatctgcc acctcaqccct cctaagtgtt ttggcaggc ggtctcgaac 600

5 cgaccggcca ctactgtott tctttgaccc ttccagttc gaagataaaag aggaaataat 660
 ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720
 atttaccgca gttggcacc taagagtatg acaaacagcaa taaaaagtaa tttcaaagag 780
 ttaagatttc ttccagcaaaa tagatgattc acatcttcaa gtccttttgc aaatcagtt 840
 ttaatattat tctttcctca ttccatctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca ggggagatgc actggcgca 960
 gcccggctca ccgcaatctc tgccacccg
 10 <210> 54
 <211> 250
 <212> DNA
 <213> Human
 15 <400> 54
 20 catttccccca ttggtcctga ttttgaagat ttagttaaag aggctgttaag tcaggttcga 60
 gcagaggcta ctacaagaag taggaaatca agtccctcac atgggctatt aaaacttagt 120
 agtggtgag tagtggaaaaa gaaatctgag caacttcata acgttaactgc ctttcaggga 180
 aaagggcatt ctttaggaac tgcattctggt aacccacacc ttgatccaag agctaggaa 240
 acttcagttg
 <210> 55
 <211> 2270
 <212> DNA
 25 <213> Human
 <400> 55
 30 gcgccccca gcagcgcccg cgccctccgc gccttctccg cgggaccc gaggcgaaaga 60
 ggcggcgccg ccgcccagcc ctgcctccc tgcccacccg gcacaccgca cggccacccc 120
 gaccccgatg cgcacggcct gtccgctgca caccagctt tggtcgctt cgtcgcccg 180
 ctcgccccgg gctactcctg cgccaccaa tggactcccg catcgccagg ggcgtcgcc 240
 tagtcgtcac cttctccac ttgaccaggc tggcgcttc caccgtcccc gctgcctgccc 300
 actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtcgg gacggctgca 360
 35 gctgctgtaa ggtctgcgc aagcagctca acgaggactg cagcaaaacg cagccctgca 420
 accacaccaa gggctggaa tgcaacttcg ggcggcaagtc caccgctctg aaggggatct 480
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaaacgggg 540
 aaagtttcca gcccaactgt aaacatctgtt gcatgttat tgatggcgcc gtgggctgca 600
 40 ttcctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac ctcggctgg 660
 tcaaagttac cggcagtgc tgcgaggagt gggctgtga cgaggatgt atcaaggacc 720
 ccatggagga ccaggacggc ctcctggca aggagctggg attcgatgcc tccgaggctgg 780
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcaactg aagcggctcc 840
 ctgttttgg aatggagcct cgcatcctat acaaccctt acaaggccag aaatgtattt 900
 ttcaaaacaac ttcatggtcc cagtgtctaa agacctgtgg aactggatc tccacacgag 960
 45 ttaccaatga caaccctgag tgccgccttg tgaaagaaac cggatttgt gaggtgcggc 1020
 cttgtggaca gccagtgtac agcagcctga aaaagggca gaaatgcagc aagaccaaga 1080
 aatccccca accagtctagg ttacttacg ctggatgttt gagttgtgaag aaataccggc 1140
 ccaagtactg cggtccctgc gtggacggcc gatgctgcac gccccagctg accaggactg 1200
 tgaagatgca gttccgctgc gaagatgggg agacatttc caagaacgtc atgatgatcc 1260
 50 agtcctgca atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
 ggctgttcaa tgacattcac aaatttaggg actaaatgtc acctgggttt ccaggccaca 1380
 cctagacaaa caaggagaa gagttgtcaga atcagaatca tggagaaaat gggcgggggt 1440
 ggtgtgggtg atgggactca ttgttagaaag gaaggcttgc tcattcttgc ggagcattaa 1500
 55 ggtatttca aactgccaag ggtgtgggtg cggatggaca ctaatgcagc cacgatttga 1560
 gaataacttg cttcatagta ttggagcaca tggactgtc tcatttttgc gcttgtggag 1620
 ttgatgactt tctgttttgc gttgttaat tatttgcata gcatattttc tctaggcttt 1680
 tttccttttgc gggttctaca gtcgtaaaag agataataag attagtttgc cagttttaaag 1740
 cttttatttgc tcctttgaca aaagtaataat ggagggcatt ccatcccttc ctgaagggggg 1800
 60 acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaaa acagaaatca 1860
 ggtgtttttaa gactgaatgt ttatattatc aaaatgttagc ttttggggag ggagggggaaa 1920
 tgaataactg gaataatttg taaatgattt taattttata ttcagtggaaa agattttattt 1980
 tatggaaatta accatttaaat aaagaaatat ttacctaata tctgagtgtt tgccattcgg 2040
 tattttttaga ggtgtccaa agtcattagg aacaaccttag ctcacgtact caatttattca 2100
 aacaggactt atgggatac agcagtgaat taagctttaaaat aaataagata atgattgctt 2160
 65 ttatacccttc agtagagaaaa agtcttgca tataaagtaa tggtaaaaaa acatgtatttgc 2220
 aacacgacat tggatgaagc acaataaaga ttctgaagct aaaaaaaaaaa

<210> 56
<211> 1636
<212> DNA
<213> Human

<400> 56

10	cttgaatgaa	gctgacaccca	agaaccgcgg	gaagagcttg	ggcccaaagc	aggaaaggga	60
	agcgctcgag	ttggaaaagga	accgctgctg	ctggccgaac	tcaagcccg	gcgccccac	120
	cagtttGatt	ggaagtccag	ctgtgaaacc	tggagcgtcg	ccttctccc	agatggctcc	180
	tggtttGCTT	ggtctcaagg	acactgcac	gtcaaactga	tcccctggcc	gttggaggag	240
	cagttcatcc	ctaaagggtt	tgaagccaaa	agccgaagta	gcaaaaatga	gacgaaagggg	300
	cggggcagcc	caaaagagaa	gacgctggac	tgtggtcaga	ttgtctgggg	gctggccttc	360
	agcccgtggc	tttccccacc	cagcaggaag	ctctggcac	gccaccaccc	ccaagtgc	420
	gatgtctctt	gcctggttct	tgctacggga	ctcaacgatg	ggcagatcaa	gatctggag	480
	gtgcagacag	ggctcctgct	tttgaatctt	tccggccacc	aagatgtcgt	gagagatctg	540
	agcttcacac	ccagtggcag	tttgattttg	gtctccgcgt	cacggataa	gactctcgc	600
	atctgggacc	tgaataaaaca	cggtaaaacag	attcaagtgt	tatcgggcca	cctgcagtgg	660
	gtttactgct	gttccatctc	cccagactgc	agcatgctgt	gctctgcagc	tggagagaag	720
	tcggtctttc	tatggagcat	gaggtcctac	acgttaattc	ggaagctaga	gggcacatcaa	780
	agcagtgttg	tctcttgtga	cttctccccc	gactctgccc	tgcttgcac	ggcttcttac	840
	gataccaatg	tgattatgtg	ggaccctac	accggcgaaa	ggctgaggc	actccaccac	900
	acccaggttg	accccgccat	ggatgacagt	gacgtccaca	ttagctcact	gagatctgtg	960
	tgcttctctc	cagaaggctt	gtaccttgcc	acgggtggcag	atgacagact	cctcaggatc	1020
	tggccctgg	aactaaaaac	tcccattgca	tttgcctcta	tgaccaatgg	gcttgctgc	1080
	acatttttc	cacatggtgg	agtcatgtcc	acagggacaa	gagatggcca	cgtccagttc	1140
	tggacagctc	ctagggtcct	gtcctcactg	aagcacttat	gccggaaagc	ccttcgaagt	1200
	ttcctaacaa	cttaccaagt	cctagcactg	ccaatcccc	agaaaaatgaa	agatccctc	1260
	acatacagga	cttttaagc	aacaccacat	cttgcgttc	ttttagcag	gttaaatcgt	1320
	cctgtcaaag	ggagttgctg	gaataatggg	ccaaacatct	ggtcttgcat	tgaaatagca	1380
	tttctttggg	attgtgaata	gaatgttagca	aaaccagatt	ccagtgtaca	taaaagaatt	1440
	tttttgtctt	taaatagata	caaatgtcta	tcaactttaa	tcaagttgt	acttatattg	1500
	aagacaattt	gatacataat	aaaaaaattat	gacaatgtcc	tggaaaaaaa	aaaatgtaga	1560
	aagatggtga	agggtggat	ggatgaggag	cgtggtgacg	ggggcctgca	gcgggttggg	1620
	gaccctgtgc	tgcgtt					

<210> 57

<211> 46

<212> DNA

<213> Human

<400> 57

45	ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcataatgt	60
	gcctccagggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa	120
	tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttcta tgcagcaggg	180
	ggcaggagcc cagcaaggga gcctccattc ccaggactt ggagggagct gagaccatcc	240
50	atgcccgcag agccctccct cacactccat cctgtccagc cctaatttg caggtgggaa	300
	aactgaggct gggaaagtac atagcaagtg actggcagag ctggactgg aaccacacca	360
	gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta	420
	ccgagctcga attcgtaatc atggtcatacg ctgtttcctg	

<210> 58

<211> 1049

<212> DNA

<213> Human

<400> 58

60 atctgatcaa gaatacctgc cctggtcact ctgcggatgt ttctgtccac ttgttcacat 60
tgaggaccaa gatatcctt tttacagagg cacttgcgtg gtctaaacaca gacacctcca 120
tgacgacatg ctggctcaca tttgcgttt ctgcagaagt cccctccca gcctggacta 180
cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agaggctggaa gcactctgaa 240
65 gtcagtgtct gtgcagggtt taccgtggct ctgcattcct caggcattaa aggtctttg 300
ggatctacaa tttttagat tttccattt tgagtctggg tcataacttt actgcttgat 360

aaaatgtaaa cttcacctag ttcatcttct ccaaatccca agatgtgacc ggaaaagtag 420
cctctacagg acccaagt gccgacacag agtggtttt ctgccactg ctttgtcaca 480
ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gttccatac 540
5 aatctttctg actggcagcc ccggatataca aatccaccaa ccaaaggacc attactaat 600
ggcttgaatt ctaaaagtga tggctcaccc tcataatctt tcccctttat tatctgtaga 660
attctggctg atgatctgtt tttccatgg gagtctgaac acagtatcgt taaattgatg 720
tttatatcag tggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
aacacttcgg gggctgggt ggtgctgtt aagtgtgggt tgcccttgg tatgaaataa 840
10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
aaccatcca tttttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
aaaaaccgt cagggccaaa gagcagttgc cctccagat gcttctgtg gagttctgca 1020
acttcaagaa agactctggc tggctcaaa

15 <210> 59
<211> 747
<212> DNA
<213> Human

20 <400> 59

20 ttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaacgtc 60
ccttaattta caaaacccca gtcattata cacattagg gatccacagt gttcaaggaa 120
cttaaatata atgtatcata ccaaccccaag taaaccaagt aaaaaaaaaata ttcatataaa 180
25 gttgttcaca cgttagtctt agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
atagatttat taacttagtat tggaaactaa cttctgtgcct ggcttaaaaac ctccctcact 300
ctcgtctgtc ccacacaaat gtttaagaag tcactgcaat gtactccccg gctctgtatg 360
aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt ctcctgtgg 420
gctctcttag aaaaccagcg ggacggccctc cctgctgata ccgtctataa ccttaggggg 480
30 ccctcgggca ggcaacggca gtggactcat ctcgggtatg gctgttagatg ctaacactgg 540
ccaattcaat gccacaccta ctggttaccc ttggaggca ttctccaga cagaagcccc 600
ttgaagccta ggttagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
gcccagtacg acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
cgcaattta gtagtaatag cgccgc